Comparison of the Clinical Effectiveness of Oseltamivir and Zanamivir against Influenza Virus Infection in Children

Sugaya, Norio; Tamura, Daisuke; Yamazaki, Masahiko; Ichikawa, Masataka; Kawakami, Chiharu; Kawaoka, Yoshihiro; Mitamura, Keiko

doi:10.1086/589748

Cited by 84 publications

(61 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the results of our previous study showed that oseltamivir is more effective clinically against influenza A (H3N2) virus infection than against influenza A (H1N1) or B virus (16,18).…”

Section: Discussionmentioning

confidence: 94%

Long-Acting Neuraminidase Inhibitor Laninamivir Octanoate (CS-8958) versus Oseltamivir as Treatment for Children with Influenza Virus Infection

Sugaya

Ohashi

2010

Antimicrob Agents Chemother

Self Cite

163

148

View full text Add to dashboard Cite

We conducted a double-blind, randomized controlled trial to compare a long-acting neuraminidase inhibitor, laninamivir octanoate, with oseltamivir. Eligible patients were children 9 years of age and under who had febrile influenza symptoms of no more than 36-h duration. Patients were randomized to 1 of 3 treatment groups: a group given 40 mg laninamivir (40-mg group), a group given 20 mg laninamivir (20-mg group), and an oseltamivir group. Laninamivir octanoate was administered as a single inhalation. Oseltamivir (2 mg/kg of body weight) was administered orally twice daily for 5 days. The primary end point was the time to alleviation of influenza illness. The primary analysis included 184 patients (61, 61, and 62 in the 40-mg group, 20-mg group, and oseltamivir group, respectively). Laninamivir octanoate markedly reduced the median time to illness alleviation in comparison with oseltamivir in patients infected with oseltamivir-resistant influenza A (H1N1) virus, and the reductions were 60.9 h for the 40-mg group and 66.2 h for the 20-mg group. On the other hand, there were no significant differences in the times to alleviation of illness between the laninamivir groups and oseltamivir group for patients with influenza A (H3N2) or B virus infection. Laninamivir octanoate was well tolerated. The most common adverse events were gastrointestinal events. Laninamivir octanoate was an effective and well-tolerated treatment for children with oseltamivir-resistant influenza A (H1N1) virus infection. Further study will be needed to confirm clinical efficacy against influenza A (H3N2) or B virus infection.

show abstract

Section: Discussionmentioning

confidence: 94%

Long-Acting Neuraminidase Inhibitor Laninamivir Octanoate (CS-8958) versus Oseltamivir as Treatment for Children with Influenza Virus Infection

Sugaya

Ohashi

2010

Antimicrob Agents Chemother

Self Cite

163

148

View full text Add to dashboard Cite

show abstract

“…One study found that peramivir alleviated fever significantly sooner (within 24 and 72 h of administration) than a placebo [4]. Oseltamivir and zanamivir similarly reduced the febrile period in children with influenza A(H3N2) [5], and laninamivir and oseltamivir were shown to be equally effective for alleviating influenza illness in children [6]. Acetaminophen was permitted as rescue in these studies.…”

Section: Discussionmentioning

confidence: 99%

Clinical Effects of Oseltamivir, Zanamivir, Laninamivir and Peramivir on Seasonal Influenza Infection in Outpatients in Japan during the Winter of 2012-2013

Takemoto¹,

Asai²,

Ikezoe³

et al. 2013

Chemotherapy

View full text Add to dashboard Cite

Background: The neuraminidase inhibitors (NAIs) oseltamivir, zanamivir, laninamivir and peramivir are available in Japan. However, the selective use of NAIs for treating outpatients with influenza has not been clearly defined. Methods: We assigned 191 patients with influenza to 4 groups, each treated with a different NAI, and then compared how long it took to alleviate fever and other symptoms and to eliminate the virus. Results: Alleviation of fever occurred significantly sooner with peramivir than with either zanamivir (p = 0.0002) or oseltamivir (p = 0.0059), but was not significantly different from that with laninamivir (p = 0.0457; p < 0.0083). Other symptoms were also alleviated sooner by peramivir than by the other 3 NAIs. Conclusions: The ability of each NAI to alleviate influenza symptoms and fever varied. The appropriate use of NAIs requires further study.

show abstract

“…Potential inhibition activities of carbamimidamido complex have previously been reported in case of WSV [23] and influenza A and B virus [26][27][28][29]. Carbamimidoylphenyl containing molecules has also been reported to inhibit Matriptase a type II transmembrane serine protease expressed in most human epithelia [30].…”

Section: Introductionmentioning

confidence: 99%

Zika Virus Serene Protease Complex (Ns2b-Ns3) Inhibition by 2-Amino-5-{[(1z)-Amino({[(z)-Benzoyl]imino})methyl]amino}-N-(5-Amino-7-{[Carbamoyl(phenyl)methyl]amino}-6-Oxoheptyl)pentanamide, in Silico Studies

Singh¹,

Merugu

Solanki³

2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective: The present in silico study is taken to report 2-amino-5-{[(1Z) -amino ({[(Z) -benzoyl] imino}) methyl] amino} -N-(5-amino-7-{[carbamoyl (phenyl) methyl] amino} -6-oxoheptyl) pentanamide as Zika virus (ZIKV) NS2B-NS3 protease inhibitor. Methods:In silico studies performed on online docking servers. NS2B-NS3 serine protease from ZIKV with PDB ID: 5GJ4 a hydrolase with total structure weight of 102878.54 is selected as the target. Docking server is used for carrying out docking calculations. Lamarckian genetic algorithm and the Solis and Wets local search methods are used for performing docking simulations. Free energy calculations, hydrogen bond (HB) formation, polar and hydrophobic interactions and HB plot are studied in this study. Results

show abstract

Comparison of the Clinical Effectiveness of Oseltamivir and Zanamivir against Influenza Virus Infection in Children

Abstract: Oseltamivir and zanamivir were equally effective in reducing the febrile period of children with influenza A (H1N1), influenza A (H3N2), and influenza B virus infection.

Cited by 84 publications

References 8 publications

Long-Acting Neuraminidase Inhibitor Laninamivir Octanoate (CS-8958) versus Oseltamivir as Treatment for Children with Influenza Virus Infection

Long-Acting Neuraminidase Inhibitor Laninamivir Octanoate (CS-8958) versus Oseltamivir as Treatment for Children with Influenza Virus Infection

Clinical Effects of Oseltamivir, Zanamivir, Laninamivir and Peramivir on Seasonal Influenza Infection in Outpatients in Japan during the Winter of 2012-2013

Zika Virus Serene Protease Complex (Ns2b-Ns3) Inhibition by 2-Amino-5-{[(1z)-Amino({[(z)-Benzoyl]imino})methyl]amino}-N-(5-Amino-7-{[Carbamoyl(phenyl)methyl]amino}-6-Oxoheptyl)pentanamide, in Silico Studies

Contact Info

Product

Resources

About